Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Pal, Gargi; Huaman, Jeannette; Levine, Fayola; Orunmuyi, Akin T.; Olapade-Olaopa, E.O.; Onagoruwa, Onayemi Titilayo; Ogunwobi, Olorunseun O.

doi:10.3390/genes10120964

Cited by 16 publications

(17 citation statements)

References 31 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation was made from comparing the relative expression of PVT1 exons in different cell lines derived from men of different ethnic and racial backgrounds. In a more recent study by the Ogunwobi laboratory, PVT1 exon 9 was found to be upregulated in prostate cancer tissues when compared to normal prostate tissues (95). This is consistent with previous studies on the expression of PVT1 exon 9 in prostate cancer cell lines (96).…”

Section: Pvt1 In Prostate Cancersupporting

confidence: 90%

Oncogenic Role of PVT1 and Therapeutic Implications

et al. 2020

Self Cite

View full text Add to dashboard Cite

PVT1, a long non-coding RNA has been implicated in a variety of human cancers. Recent advancements have led to increasing discovery of the critical roles of PVT1 in cancer initiation and progression. Novel insight is emerging about PVT1's mechanism of action in different cancers. Identifying and understanding the variety of activities of PVT1 involved in cancers is a necessity for the development of PVT1 as a diagnostic biomarker or therapeutic target in cancers where PVT1 is dysregulated. PVT1's varied activities include overexpression, modulation of miRNA expression, protein interactions, targeting of regulatory genes, formation of fusion genes, functioning as a competing endogenous RNA (ceRNA), and interactions with MYC, among many others. Furthermore, bioinformatic analysis of PVT1 interactions in cancers has aided understanding of the numerous pathways involved in PVT1 contribution to carcinogenesis in a cancer type-specific manner. However, these recent findings show that there is much more to be learned to be able to fully exploit PVT1 for cancer prognostication and therapy. In this review, we summarize some of the latest findings on PVT1's oncogenic activities, signaling networks and how targeting these networks can be a strategy for cancer therapy.

show abstract

Section: Pvt1 In Prostate Cancersupporting

confidence: 90%

Oncogenic Role of PVT1 and Therapeutic Implications

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plasmacytoma Variant Translocation 1 (PVT1) is a long non-protein-coding gene, located at chromosome 8q24 and contains approximately twelve exons and encodes a cluster of six microRNAs ( Ilboudo et al 2015 ; Colombo et al 2015 ). Several studies have reported that PVT1 plays a role in tumorigenesis, proliferation, apoptosis, cell cycle progression, migration, and invasion ( Chen et al 2018a ; Derderian et al 2019; He et al 2019 ; Pal et al 2019 ; Onagoruwa et al 2020 ). Aberrations of PVT1 are associated with different malignancies including cervical cancer, bladder cancer, colorectal cancer, gastric cancer, breast cancer, hepatocellular carcinoma, lung cancer, and breast cancer ( Wan et al 2016 ; Iden et al 2016 ; Chen et al 2018b ; Tang et al 2018 ; He et al 2019 ; Yu et al 2019 ).…”

mentioning

confidence: 99%

Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer

Pal

Orunmuyi

et al. 2020

G3 Genes|Genomes|Genetics

Self Cite

View full text Add to dashboard Cite

Genetic variation in susceptibility to complex diseases, such as cancer, is well-established. Enrichment of disease associated alleles in specific populations could have implications for disease incidence and prevalence. Prostate cancer (PCa) is a disease with well-established higher incidence, prevalence, and worse outcomes among men of African ancestry in comparison to other populations. PCa is a multi-factorial, complex disease, but the exact mechanisms for its development and progression are unclear. The gene desert located on chromosome 8q24 is associated with aggressiveness of PCa. Interestingly, the non-protein coding gene locus Plasmacytoma Variant Translocation (PVT1) is present at chromosome 8q24 and is overexpressed in PCa. PVT1 gives rise to multiple transcripts with potentially different molecular and cellular functions. In an analysis of the PVT1 locus using data from the 1000 Genomes Project, we found the chromosomal region spanning PVT1 exons 4A and 4B to be highly differentiated between African and non-African populations. We further investigated levels of gene expression of PVT1 exons 4A and 4B and observed significant overexpression of these exons in PCa tissues relative to benign prostatic hyperplasia and to normal prostate tissues obtained from men of African ancestry. These results indicate that PVT1 exons 4A and 4B may have clinical implications in PCa a conclusion supported by the observation that transient and stable overexpression of PVT1 exons 4A and 4B significantly induce greater prostate epithelial cell migration and proliferation. We anticipate that further exploration of the role of PVT1 exons 4A and 4B may lead to the development of diagnostic, therapeutic, and other clinical applications in PCa.

show abstract

“…Of note, the PVT1-217 transcript is the most abundant in the gastrointestinal tract mucosa [ 115 ]. Furthermore, PVT1 expression is elevated in multiple cancer types including lung [ 129 ], prostate [ 130 ], cervical [ 131 ], and colon [ 132 ]. Possible functional roles for PVT1 are mediated by miRNAs, and competing endogenous RNA (ceRNA), involving regulation of gene activity through C-MYC activation [ 115 , 125 , 133 ].…”

Section: The Role Of Pvt1 In the Diagnosis Treatment And Prognosimentioning

confidence: 99%

Biomarkers in Colorectal Cancer: Current Research and Future Prospects

Ogunwobi

Mahmood

Akingboye

2020

IJMS

Self Cite

157

103

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of KRAS gene mutations predicting benefit from epidermal growth factor receptor (EGFR) inhibiting antibodies. However, few biomarkers have been translated into clinical practice highlighting the need for further investigation. We review a range of protein, DNA and RNA-based biomarkers under investigation for diagnostic, predictive, and prognostic properties for CRC. In particular, long non-coding RNAs (lncRNA), have been investigated as biomarkers in a range of cancers including colorectal cancer. Specifically, we evaluate the potential role of lncRNA plasmacytoma variant translocation 1 (PVT1), an oncogene, as a diagnostic, prognostic, and therapeutic biomarker in colorectal cancer.

show abstract

Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells

Cited by 16 publications

References 31 publications

Oncogenic Role of PVT1 and Therapeutic Implications

Oncogenic Role of PVT1 and Therapeutic Implications

Population Differentiation at the PVT1 Gene Locus: Implications for Prostate Cancer

Biomarkers in Colorectal Cancer: Current Research and Future Prospects

Contact Info

Product

Resources

About